Boston Scientific Corporation (BSX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Group 1 - The company has issued a growth guidance of 10% to 11% for the fourth quarter, which is consistent with the starting point of 2025 projected growth of 10% to 12% [1] - The company expresses confidence in maintaining high double-digit growth rates despite facing challenging year-over-year comparisons [1] - Long-term investment strategies remain a priority for the company, with a focus on improving WAMGR growth [2]